Background: Peptide receptor radionuclide therapy (PRRT) could be a therapeutic option for patients with advanced, recurrent or progressing meningiomas overexpressing somatostatin receptors. The aim of this study is to perform an updated meta-analysis to establish the disease control rate of PRRT in these patients. Methods: A comprehensive literature search of studies on PRRT in patients with advanced, recurrent or progressing meningioma was carried out. Four different databases (PubMed/MEDLINE, EMBASE, Cochrane library, Google Scholar) were screened until April 2025. Only original articles about PRRT in advanced, progressive or refractory meningiomas were selected. Case reports were excluded. Three review authors independently performed the literature search, the article selection and the data extraction. Main findings of eligible studies were summarized and a proportion meta-analysis on the disease control rate was carried out using a random-effects model. Results: In total, 18 studies (269 patients) published from 2006 to 2025 were included in the analysis. In most of the included studies, PRRT was performed using [177Lu]Lu-DOTATATE. The pooled disease control rate was 67.7% (95% confidence interval values: 59.6–75.7%). PRRT was well-tolerated in most patients with advanced, recurrent or progressive meningioma. Moderate statistical heterogeneity was found in the meta-analysis (I-square: 53%). Conclusions: PRRT is an effective and well-tolerated treatment in patients with advanced, progressive or recurrent meningiomas, showing a significant disease control rate (in about two-thirds of patients). Even if well-designed clinical trials are needed to corroborate these findings, evidence-based data seem to support the clinical use of PRRT for this indication.
背景：对于表达生长抑素受体过度的晚期、复发或进展性脑膜瘤患者，肽受体放射性核素治疗（PRRT）可能是一种治疗选择。本研究旨在通过更新的荟萃分析，确定PRRT在此类患者中的疾病控制率。方法：对晚期、复发或进展性脑膜瘤患者接受PRRT治疗的相关研究进行了全面的文献检索。截至2025年4月，检索了四个不同的数据库（PubMed/MEDLINE、EMBASE、Cochrane图书馆、Google Scholar）。仅选取关于PRRT治疗晚期、进展性或难治性脑膜瘤的原创性研究，排除病例报告。三位综述作者独立进行文献检索、文章筛选和数据提取。总结符合条件研究的主要发现，并使用随机效应模型对疾病控制率进行比例荟萃分析。结果：共纳入2006年至2025年间发表的18项研究（269例患者）。在大多数纳入的研究中，PRRT使用的是[¹⁷⁷Lu]Lu-DOTATATE。汇总的疾病控制率为67.7%（95%置信区间：59.6%–75.7%）。对于大多数晚期、复发或进展性脑膜瘤患者，PRRT耐受性良好。荟萃分析发现存在中度统计学异质性（I²：53%）。结论：PRRT是治疗晚期、进展性或复发性脑膜瘤患者的一种有效且耐受性良好的治疗方法，显示出显著的疾病控制率（约三分之二的患者）。尽管仍需设计良好的临床试验来证实这些发现，但基于证据的数据似乎支持PRRT在此适应症中的临床应用。
肿瘤(癌症)患者之家